Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

Philip D Harvey, Masaaki Ogasa, Josephine Cucchiaro, Antony Loebel, Richard S E Keefe

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Methods: Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once daily (N = 150) or ziprasidone 80 mg BID (N = 151). A similar proportion of patients completed the study on lurasidone (67.5%) and ziprasidone (69.3%). Study participants were assessed with the majority of the tests from the MATRICS Consensus Cognitive Battery (MCCB) and an interview-based assessment of cognitive functioning, the Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based on the interviewer's best judgment, after interviews with the patient and a caregiver when available. The study was conducted from April 2006 to January 2007. Results: There were no between-group treatment differences in performance on the MCCB or the SCoRS ratings. Lurasidone patients demonstrated significant within group-improvement from baseline on the MCCB composite score (p = 0.026) and on the SCoRS (p < 0.001), but ziprasidone patients did not improve on either the MCCB composite (p = 0.254) or the SCoRS (p = 0.185). At endpoint there was a statistical trend (p = 0.058) for lurasidone to demonstrate greater improvement from baseline in SCoRS ratings. Improvements in interview-based aspects of cognition were not related to MCCB test changes, and had minimal correlations with changes in symptoms. Conclusions: These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3 weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures.

Original languageEnglish
Pages (from-to)188-194
Number of pages7
JournalSchizophrenia Research
Volume127
Issue number1-3
DOIs
StatePublished - Apr 1 2011

Fingerprint

Schizophrenia
Cognition
Interviews
Consensus
Lurasidone Hydrochloride
ziprasidone
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Psychotic Disorders
Caregivers
Outpatients
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Antipsychotic
  • Lurasidone
  • Neuropsychology
  • Schizophrenia
  • Ziprasidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. / Harvey, Philip D; Ogasa, Masaaki; Cucchiaro, Josephine; Loebel, Antony; Keefe, Richard S E.

In: Schizophrenia Research, Vol. 127, No. 1-3, 01.04.2011, p. 188-194.

Research output: Contribution to journalArticle

Harvey, Philip D ; Ogasa, Masaaki ; Cucchiaro, Josephine ; Loebel, Antony ; Keefe, Richard S E. / Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. In: Schizophrenia Research. 2011 ; Vol. 127, No. 1-3. pp. 188-194.
@article{b4c30276e72249508443bdb17d2b0e92,
title = "Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone",
abstract = "Background: Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Methods: Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once daily (N = 150) or ziprasidone 80 mg BID (N = 151). A similar proportion of patients completed the study on lurasidone (67.5{\%}) and ziprasidone (69.3{\%}). Study participants were assessed with the majority of the tests from the MATRICS Consensus Cognitive Battery (MCCB) and an interview-based assessment of cognitive functioning, the Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based on the interviewer's best judgment, after interviews with the patient and a caregiver when available. The study was conducted from April 2006 to January 2007. Results: There were no between-group treatment differences in performance on the MCCB or the SCoRS ratings. Lurasidone patients demonstrated significant within group-improvement from baseline on the MCCB composite score (p = 0.026) and on the SCoRS (p < 0.001), but ziprasidone patients did not improve on either the MCCB composite (p = 0.254) or the SCoRS (p = 0.185). At endpoint there was a statistical trend (p = 0.058) for lurasidone to demonstrate greater improvement from baseline in SCoRS ratings. Improvements in interview-based aspects of cognition were not related to MCCB test changes, and had minimal correlations with changes in symptoms. Conclusions: These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3 weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures.",
keywords = "Antipsychotic, Lurasidone, Neuropsychology, Schizophrenia, Ziprasidone",
author = "Harvey, {Philip D} and Masaaki Ogasa and Josephine Cucchiaro and Antony Loebel and Keefe, {Richard S E}",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.schres.2011.01.004",
language = "English",
volume = "127",
pages = "188--194",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

AU - Harvey, Philip D

AU - Ogasa, Masaaki

AU - Cucchiaro, Josephine

AU - Loebel, Antony

AU - Keefe, Richard S E

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Methods: Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once daily (N = 150) or ziprasidone 80 mg BID (N = 151). A similar proportion of patients completed the study on lurasidone (67.5%) and ziprasidone (69.3%). Study participants were assessed with the majority of the tests from the MATRICS Consensus Cognitive Battery (MCCB) and an interview-based assessment of cognitive functioning, the Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based on the interviewer's best judgment, after interviews with the patient and a caregiver when available. The study was conducted from April 2006 to January 2007. Results: There were no between-group treatment differences in performance on the MCCB or the SCoRS ratings. Lurasidone patients demonstrated significant within group-improvement from baseline on the MCCB composite score (p = 0.026) and on the SCoRS (p < 0.001), but ziprasidone patients did not improve on either the MCCB composite (p = 0.254) or the SCoRS (p = 0.185). At endpoint there was a statistical trend (p = 0.058) for lurasidone to demonstrate greater improvement from baseline in SCoRS ratings. Improvements in interview-based aspects of cognition were not related to MCCB test changes, and had minimal correlations with changes in symptoms. Conclusions: These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3 weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures.

AB - Background: Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Methods: Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once daily (N = 150) or ziprasidone 80 mg BID (N = 151). A similar proportion of patients completed the study on lurasidone (67.5%) and ziprasidone (69.3%). Study participants were assessed with the majority of the tests from the MATRICS Consensus Cognitive Battery (MCCB) and an interview-based assessment of cognitive functioning, the Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based on the interviewer's best judgment, after interviews with the patient and a caregiver when available. The study was conducted from April 2006 to January 2007. Results: There were no between-group treatment differences in performance on the MCCB or the SCoRS ratings. Lurasidone patients demonstrated significant within group-improvement from baseline on the MCCB composite score (p = 0.026) and on the SCoRS (p < 0.001), but ziprasidone patients did not improve on either the MCCB composite (p = 0.254) or the SCoRS (p = 0.185). At endpoint there was a statistical trend (p = 0.058) for lurasidone to demonstrate greater improvement from baseline in SCoRS ratings. Improvements in interview-based aspects of cognition were not related to MCCB test changes, and had minimal correlations with changes in symptoms. Conclusions: These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3 weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures.

KW - Antipsychotic

KW - Lurasidone

KW - Neuropsychology

KW - Schizophrenia

KW - Ziprasidone

UR - http://www.scopus.com/inward/record.url?scp=79952316290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952316290&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2011.01.004

DO - 10.1016/j.schres.2011.01.004

M3 - Article

C2 - 21277745

AN - SCOPUS:79952316290

VL - 127

SP - 188

EP - 194

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -